Table 6

Answers to multiple choice questions of survey section 2 for Campania region

QuestionsMultiple-choice responsesAll, n (%)CC, n (%)UH, n (%)GH, n (%)
N=38N=10N=12N=16
1. Do you have any preference in the schedule of ICI choice for the treatment of CPs?☐ Yes, I prefer the schedule with the shorter interval4 (10.5)0 (0)3 (25)1 (6.3)
☐ Yes, I prefer the schedule with the longer interval18 (47.4)6 (60)5 (41.7)7 (43.8)
☐ No, the schedule interval is not a criteria for ICI choice in my clinical practice16 (42.1)4 (40)4 (33.3)8 (50)
2. Do you have currently (during COVID-19 pandemic) any preference in the schedule of ICIs for the treatment of CPs?☐ Yes, I prefer the schedule with the shorter interval0 (0)0 (0)0 (0)0 (0)
☐ Yes, I prefer the schedule with the longer interval28 (73.7)7 (70)8 (66.7)13 (81.3)
☐ No, the schedule interval is not a criteria for ICI choice in my current clinical practice10 (26.3)3 (30)4 (33.3)3 (18.8)
3. Have you modified the dose of steroids you give in case of ICI adverse events?☐ Yes, I have reduced the dose1 (2.6)0 (0)0 (0)1 (6.3)
☐ No, I continue to follow the recommendation for the AE management37 (97.4)10 (100)12 (100)15 (93.8)
4. Has the COVID-19 pandemic changed your treatment choice for CP-ICI in case of alternative treatments like chemotherapy, where applicable, as for clinical practice guidelines?☐ Yes4 (10.5)0 (0)2 (16.7)2 (12.5)
☐ No34 (89.5)10 (100)10 (83.3)14 (87.5)
5. Has the COVID-19 pandemic changed your treatment choice for CP-ICI in case of alternative treatments like targeted therapy, where applicable, as for clinical practice guidelines?☐ Yes6 (15.8)2 (20)4 (33.3)0 (0)
☐ No32 (84.2)8 (80)8 (66.7)16 (100)
6. Are the CP-ICI preferentially seen in COVID-19 clear institutions?☐ Yes14 (36.8)2 (20)7 (58.3)5 (31.3)
☐ No24 (63.2)8 (80)5 (41.7)11 (68.8)
7. Do you use G-CSF in case of CP-ICIs with no febrile neutropenia (when used ±chemotherapy)?☐ Yes9 (23.7)3 (30)4 (33.3)2 (12.5)
☐ No29 (76.3)7 (70)8 (66.7)14 (87.5)
8. Has this decision been changed by the COVID-19 pandemic?☐ Yes4 (10.5)1 (10)1 (8.3)2 (12.5)
☐ No34 (89.5)9 (90)11 (91.7)14 (87.5)
9. Have the CP-ICI been managed in expert centers for immunotherapy?☐ Yes26 (68.4)8 (80)10 (83.3)8 (50)
☐ No12 (31.6)2 (20)2 (16.7)8 (50)
10. Has this decision been changed by the COVID-19 pandemic?☐ Yes1 (2.6)0 (0)0 (0)1 (6.3)
☐ No37 (97.4)10 (100)12 (100)15 (93.8)
11. Do you prefer to delay ICI start in lung cancer patients because of potential lung toxicity considering the high lung tropism of SARS-CoV-2 virus and its risk of ARDS?☐ Yes2 (5.3)0 (0)2 (16.7)0 (0)
☐ No36 (94.7)10 (100)10 (83.3)16 (100)
12. In your institution, has surgery for CP been delayed because of the COVID-19 pandemic?☐ Yes16 (42.1)1 (10)9 (75)6 (37.5)
☐ No22 (57.9)9 (90)3 (25)10 (62.5)
  • ARDS, acute respiratory distress syndrome; CC, cancer center; CP, cancer patient; CP-ICI, cancer patients undergoing or candidate for immune checkpoint inhibitor; G-CSF, granulocyte colony stimulating factor; GH, general hospital; ICI, immune checkpoint inhibitor; N, number; UH, university hospital.